Wuhan-based CDMO Dinacon Bio Announces Over $190 Million Series A+ Financing to Accelerate Capacity Expansion

VCBeat has learned that Wuhan-based, world-class biologics contract development and manufacturing organization (CDMO) Biologics Manufacturing Corporation (Dingkang Bio) announced today that it has signed documents for over $190 million in Series A+ financing and completed the first closing of over $100 million. The round was led by VMS Group, with participation from Fidelity International and Panacea Venture. Prior to this, the company completed a $125 million Series A financing round in early 2020.

Hubei Dingkang Biotech Co., Ltd. is located in the Optics Valley Bio-City in Wuhan, China, and operates the world’s first modular biopharmaceutical manufacturing facility (GE KuBio). The facility complies with ICH, FDA, EMA, and NMPA standards. As a professional CDMO specializing in biological products, Hubei Dingkang Biotech boasts an experienced team of experts and state-of-the-art equipment, providing comprehensive CMC services from early-stage development to commercial manufacturing. Since commencing operations in 2016, the company has successfully delivered high-quality biological products to all clients and completed nearly 30 large-scale GMP production batches at the 2,000-liter scale, achieving a 100% batch success rate. With extensive expertise in technology transfer, process scale-up, process characterization, and process performance qualification, Hubei Dingkang Biotech is well-prepared to support regulatory inspections for the commercial manufacturing of its clients’ marketed products.

Phase I Plant

To meet the growing demand for CDMO services, Hubei Dingkang Biotech Co.,Ltd has launched Phase II construction, with a plan to establish an integrated CDMO industrial base featuring over 140,000 liters of total production capacity for biologics R&D and commercial manufacturing within approximately five years.

Proposed Plant for Phase II Construction

“The successful completion of this round of financing will further accelerate Dingkang Biotech’s capacity expansion,” said Mr. Huang Ruijin, Executive Chairman of Hubei Dingkang Biotech Co., Ltd. “Amid the rapid growth of China’s biopharmaceutical market and the surging demand for CDMO services, Dingkang Biotech will further strengthen its traditional advantages by prioritizing quality and leveraging commercial-scale manufacturing capabilities to rapidly become a leading biopharmaceutical CDMO in China.”

Mr. Wu Zhaowei, Head of Healthcare Investment at Dingpei Group, stated, “We are highly optimistic about Dingkang Biotech’s established service expertise and market foundation. Through our investment, we aim to accelerate Dingkang Biotech’s rapid growth, enabling it to secure a strong position in the biologics CDMO market in China and globally.”

“We are deeply honored to have earned the trust and recognition of internationally renowned investment institutions. We will continue to enhance our technology platform and expand production capacity to deliver more high-quality services to our customers. We also welcome biopharmaceutical partners from around the world to visit Dingkang Biotech to exchange insights and explore opportunities for mutual growth,” said Dr. Zeng Xianfang, CEO of Dingkang Biotech.

Hubei Dingkang Biotech Co.,Ltd is a world-class CDMO headquartered in Wuhan, Hubei. Adhering to a customer-centric approach, we are committed to delivering timely, cost-effective, and high-quality services. We provide one-stop comprehensive solutions supporting every stage from early drug development through late-stage clinical research to commercial cGMP manufacturing, thereby meeting the dynamic needs of the rapidly evolving biopharmaceutical industry. We pledge to leverage technological and production innovations to make internationally standardized biologics affordable for patients worldwide, advancing therapeutic standards to improve human health.

Hubei Dingkang Biotech Co., Ltd. has obtained a Drug Production License issued by the Hubei Provincial Medical Products Administration and achieved ISO 14001:2015 and ISO 45001:2018 certifications. Equipped with state-of-the-art facilities, a world-class team of experts, and an internationally standardized management system, the company is committed to pursuing excellence and upholding integrity as its core principle. Hubei Dingkang Biotech operates the world’s first GE KuBio modular facility in Optics Valley Bio-city, East Lake High-Tech Development Zone, China. In the near future, its total production capacity will exceed 140,000 liters.

Dingpei Group is a leading diversified financial group, offering services in asset management (private equity, real estate investment, and structured finance), securities brokerage, and corporate finance advisory. In private equity, the Group focuses on innovation and growth opportunities in key sectors such as healthcare, Technology, Media, and Telecommunications (“TMT”), and consumer industries. The Dingpei Healthcare team is dedicated to identifying outstanding global innovative healthcare companies that address unmet clinical needs, with investment areas spanning therapeutics, diagnostics, and comprehensive health management services. To date, Dingpei Group has successfully completed over 100 investments both within and outside China, with total assets under management exceeding USD 3.8 billion.

Fidelity International provides investment solutions and services, as well as specialized retirement planning, to more than 2.5 million clients worldwide. As a private company with over 50 years of history, we remain purpose-driven, focused on the next generation, and committed to long-term investment strategies. Operating in more than 25 regions globally, Fidelity International manages total assets of $706.3 billion, serving banks, sovereign wealth funds, large corporations, financial institutions, insurance companies, wealth management firms, and individual investors.

Our Retirement and Personal Investing business units provide world-class investment options, solutions, management services, and pension guidance to individual investors, advisors, and employers. Together with our Investment Solutions and Services business unit, Fidelity International manages total client assets of $541.6 billion. By leveraging our asset management expertise and integrating it with the solutions we offer for workplace pensions and personal investing, we are committed to building a better financial future.

RuiFu Healthcare Fund focuses on investing in and incubating early- and growth-stage companies worldwide that are driven by R&D innovation and possess high technological barriers in the life sciences and healthcare sectors. We aim to address unmet medical needs and improve patients’ quality of life through breakthrough technologies and inventions. Our investment team comprises the former life sciences investment team from KPCB China, a globally renowned venture capital firm, along with seasoned industry experts.